Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Enters Shutdown Mode: Reviews Will Continue, But Will Morale?

Executive Summary

User fee funding will allow many functions to continue, but only 58% of staff will be retained until funding deal is reached.

You may also be interested in...



Shutdown Winds Down: Short 'Lapse Period' Likely Means Few Disruptions At US FDA

FDA lost one work day to the shutdown, but staff may require more time to catch up again.

US FDA Communications Stand Out In Shut Down

Commissioner Gottlieb continues to hit all the right notes in his public communications since taking over FDA. His soothing words during the brief government shutdown are the latest example.

Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg

The FDA commissioner tells a House subcommittee that a job candidate questioned whether the “uncertainty” of government work was worth leaving academia, creating another hurdle for agency efforts to fill senior leadership positions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel